ABSTRACT Plasmodium falciparum infections leading to malaria have severe clinical manifestations and high mortality rates. Chloroquine (CQ), a former mainstay of malaria chemotherapy, has been rendered ineffective due to the emergence of widespread resistance. Recent studies, however, have unveiled a novel mode of action in which low-micromolar levels of CQ permeabilized the parasite's digestive vacuole (DV) membrane, leading to calcium efflux, mitochondrial depolarization, and DNA degradation. These phenotypes implicate the DV as an alternative target of CQ and suggest that DV disruption is an attractive target for exploitation by DVdisruptive antimalarials. In the current study, high-content screening of the Medicines for Malaria Venture (MMV) Pathogen Box (2015) was performed to select compounds which disrupt the DV membrane, as measured by the leakage of intravacuolar Ca 2ϩ using the calcium probe Fluo-4 AM. The hits were further characterized by hemozoin biocrystallization inhibition assays and dose-response half-maximal (50%) inhibitory concentration (IC 50 ) assays across resistant and sensitive strains. Three hits, MMV676380, MMV085071, and MMV687812, were shown to demonstrate a lack of CQ cross-resistance in parasite strains and field isolates. Through systematic analyses, MMV085071 emerged as the top hit due to its rapid parasiticidal effect, low-nanomolar IC 50 , and good efficacy in triggering DV disruption, mitochondrial degradation, and DNA fragmentation in P. falciparum. These programmed cell death (PCD)-like phenotypes following permeabilization of the DV suggests that these compounds kill the parasite by a PCD-like mechanism. From the drug development perspective, MMV085071, which was identified to be a potent DV disruptor, offers a promising starting point for subsequent hit-to-lead generation and optimization through structure-activity relationships.
cellular events, such as mitochondrial outer membrane permeabilization (MOMP) and DNA degradation. These phenotypes were similar to the hallmark features of mammalian programmed cell death (PCD), indicating an alternative mode of action for the drug, allowing it to be repurposed, despite the resistance to the drug. Furthermore, given that the parasite's DV is the major organelle for metabolic activities and its contents represent important and viable drug targets (8) , the findings provide exciting possibilities for the rational design of novel antimalarial drugs targeting the DV.
Following the success of Malaria Box, the Medicines for Malaria Venture (MMV) assembled the Pathogen Box (2015), consisting of 400 diverse compounds active against the malaria parasite and pathogens responsible for a wide range of neglected tropical diseases. A high-content screening assay capitalizing on conventional flow cytometry capabilities alongside high-resolution single-cell imaging was developed and performed to select Pathogen Box compounds that disrupt the DV membrane. Due to the abundance of calcium in the parasite's DV (9) , Ca 2ϩ release into the cytosol could serve as a surrogate indication of DV permeabilization (10) , and DV disruption was thus quantified by measurement of the amount of intravacuolar Ca 2ϩ that was leaked using a fluorescent calcium-binding probe, Fluo-4 AM. Following the disruption of the DV, mitochondrial dysfunction and DNA fragmentation were assayed to validate PCD-like features as consequences of DV membrane perturbation.
To narrow the panel of primary hits, follow-on characterization studies were conducted to investigate their possible mechanisms of action and therapeutic potencies in a time-and dose-dependent manner across laboratory strains and field isolates. These characterization assays led to the identification of a potent, non-CQ-and nonartemisinin-cross-resistant, rapidly parasiticidal, and DV-permeabilizing hit from the MMV Pathogen Box repository with activity against P. falciparum, MMV085071.
RESULTS
High-content screening of DV-permeabilizing molecules from MMV Pathogen Box. After gating for focused and circular singlets, the trophozoite population was determined in accordance with positive Hoechst staining and visual inspection of bright-field images (Fig. 1a) . Given that the DV is a calcium ion store (9) , a compromised DV membrane integrity leading to subsequent Ca 2ϩ efflux could be indicated by an increase in the area of green Fluo-4 fluorescence upon high-affinity binding to Ca 2ϩ (11) . Quantification of the Fluo-4 fluorescence redistribution (Fig. 1b to d ) was measured by the application of an area feature mask built in to the analysis software. To exclude nonspecific background staining or staining of the erythrocyte, only areas with intensities of greater than 250 pixels were incorporated for each single-cell analysis. To qualify as a DV-disrupting hit from the primary screen, the Pathogen Box compound had to display a phenotype with at least a 70% efficiency of DV disruption relative to that for CQ. Figure 1e shows the identity of the hits obtained from repeated rounds of screening. From the total of 400 Pathogen Box compounds, 10 of them produced at least a 70% increase in the area of Fluo-4 fluorescence when they were used at 10 M, giving an overall hit rate of 2.5%. Of note, MMV676380 and MMV032967 permeabilized the parasite DV to a greater extent than CQ (Fig. 1f) . Since the mechanisms of action of the compounds in the library are unknown, the phenotypic screen could offer preliminary mechanistic insights into their potential antimalarial activities.
Downstream induction of PCD-like features.
To validate PCD-like parasite cell death following DV disruption, parasites were treated with the panel of hits for 10 h for detection of downstream cellular responses. To this end, the ratiometric cationic dye JC-1 was used to characterize the perturbation of mitochondrial integrity. After normalization to the results obtained with the drug-free control (treated with phosphatebuffered saline [PBS] ), all the hits, including CQ, brought about the disintegration of the mitochondrial transmembrane potential, while CQ displayed the greatest degree of reduction in the JC-1 red-to-green ratio (Fig. 2a) . Corroborative results were obtained from the measurement of the proportion of parasites with a sub-G 1 DNA content (Fig.  2b) . Of particular note, MMV687248 demonstrated a high degree of efficacy in trigger-ing DNA fragmentation that was similar to that of CQ, while the remaining hits led to a minimum of a 3-fold increase in the proportion of sub-G 1 DNA-positive parasites. All in all, these assays also validated parasite cell death after compromise of the parasitic vacuole by the compounds and were in agreement with a novel mechanism of P. falciparum cell death following the disruption of DV integrity.
Spectrophotometric investigation of ␤-hematin biocrystallization. With the hits' PCD-like features being validated through repeated screens for MOMP and sub-G 1 DNA assays, the hits were subjected to further characterization studies to increase our understanding of the novel compounds. During the intraerythrocytic stage of the malaria parasite, hemoglobin is degraded for amino acids and osmotic homeostasis as the parasite matures in size (12) . As cytotoxic heme is generated alongside the degradation process, the parasites detoxify free monomeric heme into hemozoin biocrystals. While many theories proposing the antimalarial mechanism exerted by CQ have been developed, it is generally accepted that the drug acts by inhibiting the formation of hemozoin, thereby leading to heme accumulation and parasite cell death (13) . Despite the effectiveness of CQ and its impact on the ambitious goal of the elimination of malaria, resistance to CQ had limited its administration. Against this Following DV disruption, 3D7 parasites were treated with the hits for 10 h and assayed for mitochondrial depolarization normalized to that for the drug-free control (PBS) (a), and the percentage of parasites with sub-G 1 DNA contents was determined via flow cytometry (b). As shown from the low JC-1 red/JC-1 green ratio and the increased percentage of parasites with sub-G 1 DNA peaks, all the hits induced downstream cell death features after having disrupted the parasite's DV. As previously reported (55) , MQ was observed to induce a high percentage of sub-G 1 DNA-positive parasites but not mitochondrial dysfunction at 10 M. ***, P Ͻ 0.001 compared to the drug-free PBS-treated control.
backdrop, a de novo ␤-hematin assay was optimized to investigate the mode of action of the hits and to distinguish the activity of the novel non-CQ-like hits from that of CQ-like compounds, indicated by the low levels of ␤-hematin present in the final pellet after washing off of the monomeric heme and heme oligomeric aggregates with an alkaline bicarbonate buffer (14) . Pyrimethamine (PYR) was used as a negative mechanistic control to indicate the non-CQ-like effect, as it is an established antimalarial drug whose potency is attributed to its interference with DNA synthesis (15) . Accordingly, absorbance readings resulting from unimpeded ␤-hematin polymerization were observed to be higher for PYR and non-CQ-like hits than for CQ, which impeded ␤-hematin formation and thus resulted in lower absorbance readings. MMV676380, MMV085071, and MMV687812 emerged as hits which displayed high optical densities at 405 nm comparable to the optical density of PYR after normalization to the results for the drug-free (PBS) controls (Fig. 3) . This preliminary finding suggested that the three compounds from Pathogen Box are non-CQ cross-resistant and thus display potent activity against CQ-resistant P. falciparum strains.
Growth inhibition assay and potency across CQ-resistant strains. As the Pathogen Box is an assembly of diverse novel compounds with activity against the pathogens responsible for neglected tropical diseases of interest, meaningful antimalarial activity in the low-micromolar range had to be established prior to any subsequent hit-to-lead optimization. Laboratory strains 3D7, which is CQ sensitive, and K1, which is CQ resistant, were treated with 11-point serial dilutions of MMV676380, MMV085071, and MMV687812 for half-maximal (50%) inhibitory concentration (IC 50 ) determination, and all the sigmoidal IC 50 curves obtained had a goodness of fit above 0.97 ( Fig. 4 ; see also Fig. S1 in the supplemental material). The respective resistance indices after 48 h of incubation were then evaluated by determination of the ratio of the IC 50 for K1 to the IC 50 for 3D7 ( Table 1 ). The antimalarial efficacies of the hit compounds were determined to be in the nanomolar to low-micromolar range, with MMV085071 exhibiting the lowest IC 50 . In particular, MMV676380 and MMV085071 were phenotypically validated to be non-cross-resistant, with similar dosages required for activity against 3D7 and K1, thereby substantiating the preliminary findings obtained and shown in Fig. 3 , while a concentration of CQ 22 times greater was required for activity against K1. The IC 50 of MMV687812, however, was slightly significantly different from the IC 50 s of the other compounds, with a concentration of MMV687812 approximately 2-to 3-fold greater than that of the other compounds being needed to inhibit K1.
Dose-dependent effects of DV destabilization and PCD-like phenotype induction. Having demonstrated the lack of CQ cross-resistance, parasites were then subjected to various concentrations of the hit compounds to quantitate the minimum dose required for induction of hallmark features of PCD for evaluation of their potencies. MMV085071 was shown to achieve a notable DV disruption and MOMP and to increase the amount of sub-G 1 DNA at a dosage comparable to that of CQ on the basis of sigmoidal dose-response curves (Fig. 5a to c) . Calculation of the 70% effective concentration (EC 70 ) revealed the minimum doses required for 70% maximal phenotype induction ( Table 2) . CQ proved to display the greatest potency in eliciting the DV disruption and PCD-like phenotypes in 3D7 parasites. At least 1 M CQ was required to be accumulated in the DV of parasites for potent permeabilization in 4 h, causing mitochondrial dysfunction and DNA fragmentation in 10 h. MMV687812, in contrast, required the highest dosage to achieve all 3 investigated phenotypes. MMV676380 appeared to be the most effective in compromising parasite DNA integrity, while MMV687812 targeted the mitochondria with the most pronounced efficacy compared to its DV-disrupting and DNA degradation capacities.
FIG 4
Phenotypic validation of non-CQ-cross-resistant hits' antimalarial activities and potencies against CQ-sensitive (3D7) and CQ-resistant (K1) strains with an in vitro sensitivity IC 50 evaluation. Error bars represent SEMs from at least 3 separate experiments. ***, P Ͻ 0.001 between CQ-treated 3D7 and K1 parasites; ns, the IC 50 s obtained for MMV676380 (P ϭ 0.235) and MMV085071 (P ϭ 0.096) were not significantly different between 3D7 and K1; *, P Ͻ 0.05 for slight cross-resistance (P ϭ 0.016) for MMV687812. Assessment of parasite killing speed. Using two-color flow cytometry, the timing of action of the non-CQ-like hits for viability and reinvasion capacity was characterized at the 24th-, 48th-, and 72nd-hour time points after treatment of the parasites with the drugs of interest. 3D7 parasites were exposed to 10 times the predetermined IC 50 (Table S1 ) to avoid suboptimal drug treatment during the period of investigation (16) . This concentration was optimized by Sanz et al. (16) , who demonstrated that concentrations corresponding to 10 times the IC 50 warranted the maximal in vitro killing activity irrespective of the mode of action. As such, should an effect of delayed parasite death be observed, it would be associated with the timing of action and the killing kinetics of the drug and not suboptimal drug exposure. Optimization and validation of the assay were first achieved with 4 established antimalarials that exhibit distinctive a EC 70 was calculated for the evaluation of potency in inducing PCD-like phenotypes, as a 70% cutoff was applied for the selection of hits during the high-content primary screen (Fig. 1e ).
killing rate profiles on the basis of the double carboxyfluorescein diacetate succinimidyl ester (CFDA-SE)-and Hoechst-positive population (Fig. S2 ). The double-positive population correlates with viable parasites that are able to invade fresh uninfected CFDA-SE-labeled erythrocytes. The killing rate profiles obtained were in agreement with the findings of pharmacokinetic studies, as atovaquone (ATV) and PYR have been known to exert their inhibitory effects more slowly than CQ and artesunate (ART), which are rapidly acting antimalarials (17) . ATV collapses the mitochondrial membrane potential by binding to the parasite cytochrome b complex, and despite its potent interference with parasite proliferation, it produces a delayed death phenotype, where a considerable decline in the level of parasitemia could be detected only beyond the 72nd hour of the P. falciparum life cycle (17) (18) (19) . In order to investigate parasite killing kinetics, flow cytometric analysis was repeated up to the 72nd-hour time point for dynamic coverage of the parasite life cycle. Of the three non-cross-resistant hits, MMV085071 was demonstrated to be a fast-acting parasiticidal agent which lowered the level of parasitemia to 30% of that at the beginning within the first 24 h, while MMV687812 and MMV676380 displayed notable inhibitory action only after the 24th-to 48th-hour time points (Fig. 6) . Dose-response assays on ART-sensitive and -resistant strains. Thus far, MMV676380, MMV085071, and MMV687812 have been demonstrated to be DV disruptive and effective against both CQ-resistant and -sensitive strains. In particular, MMV085071 was also shown to be a fast-acting compound that targeted parasite growth within the first 24 h of the life cycle. Due to artemisinin resistance from the delayed parasite clearance associated with a single nucleotide mutation in the parasite's Kelch13 protein (20) , it is pertinent to evaluate the applicability and efficacy of the three hit compounds against ART-sensitive and -resistant strains. IPC 5202 is an ART-resistant strain with an R539T polymorphism in the Kelch13 propeller domain. Isolated in 2011 from a western Cambodia malaria patient, it showed delayed clearance and 40 to 49% survival in in vitro artemisinin-based susceptibility tests (21) . Cam3.I_rev is a revertant of IPC 5202 that is susceptible to ART. A 48-h reinvasion assay was performed, and the 3 compounds demonstrated comparable potencies (IC 50 s) with nonsignificant differences in activity according to the P values, regardless of the delayed parasite clearance status (Fig. 7) , thereby suggesting the lack of crossresistance to ART. On the contrary, resistant strain IPC 5202 required an 8-fold increase in the ART concentration for a half-maximal inhibitory effect compared to the concentration required for activity against sensitive strain Cam3.I_rev. 
DISCUSSION
Drug discovery campaigns often rely on 2 different approaches: target-based screening and phenotypic screening. While well-defined mechanisms of action may be elucidated and molecular hypotheses can be investigated through target-based screening, target-based screening also contributes to high attrition rates and low levels of effectiveness in the subsequent drug development pipeline as specific molecular pathways and interactions increase in complexity in relation to disease pathogenesis and therapy (22) . Phenotype-driven screenings, on the other hand, pose challenges in the optimization of drug candidates due to the lack of limited mechanistic studies. Yet first-in-class drugs with novel molecular entities and scaffolds could be developed due to the diverse screening strategy harnessed through a phenotype-centric approach. In the current study, we adopted a target (DV)-based phenotypic screen which leverages the strengths of both approaches. As such, in the first-pass screening, the MMV Pathogen Box library was screened for compounds that, at a concentration of 10 M, produced phenotypes of DV permeabilization, MOMP, and DNA degradation ( Fig. 1 and  2 ). Even though PCD in P. falciparum had been a contentious topic, growing evidence had substantiated the existence of apoptotic features during both the intraerythrocytic stage (23) (24) (25) and the mosquito stage (26, 27) of development. Our work presents a robust combination of target-based phenotypic screening alongside downstream validation using MOMP and DNA degradation assays, in accordance with the hallmark characteristics of mammalian apoptosis. Altogether, these findings corroborate the emerging indication that the mitochondrial and DNA degradation PCD phenotypes, whether they are incidental or genetically encoded, can be readily observed in P. falciparum through exposure to physiological stress, drug treatment, and external stimuli.
The MMV Pathogen Box contains 400 novel drug-like compounds active against a wide range of pathogens responsible for infectious tropical diseases and pathogenic helminths. With a hit rate of 2.5% (10/400), 6 of them were from the malaria disease cluster set, while the remaining 4 were from the tuberculosis disease set ( Table 3) . As these 4 hits exhibited activity against both Mycobacterium tuberculosis and P. falciparum, it is plausible that they exert overlapping mechanisms of action. Common enzymatic complexes of the type II fatty acid biosynthetic pathway and/or the isoprenoid biosynthetic pathway(s) in both pathogens suggest possible putative drug targets. This notion is supported by emerging reports on the antimalarial and antimycobacterial activities of antibiotics inhibiting the FabI and FabH enzymes of the type II fatty acid synthesis (FAS) pathway, which is common to both microorganisms (28) (29) (30) (31) . Since the type II FAS pathway is the only means of de novo fatty acid biosynthesis in malaria parasites (32), a possible antimalarial mechanism of action of the 4 hits from the tuberculosis disease set may involve the common FAS pathway. This preliminary screen could henceforth promote an understanding of the pathogenesis of these two deadliest infectious diseases. From the supporting information for the MMV data set, all 10 hits have 1-octanol/water partition coefficient (clogP) values ranging from 1.9 to 3.4 and pK a values ranging from 7.0 to 11.4. A high-content screen recently found that compounds with clogP values above 2 and basic pK a values ranging from 6.5 to 11.0 are readily able to diffuse into lysosomes (33) . These physiochemical properties are in agreement with the lysosomal accumulation of chemotherapeutics, such as CQ and quinacrine, due to their weak basicity and lipophilicity. Various anticancer drugs and tricyclic antidepressants with weak basicity and lipophilicity have also been shown to exert their therapeutic effects through lysosomal sequestration (34) . In light of these findings, it can be postulated that the panel of hits permeabilized the parasite's DV membrane, by this means resulting in the downstream release of calcium ions and apoptosis-like cellular phenotypes. Information previously published in the literature associates P. falciparum CQ resistance with P. falciparum crt (pfcrt) gene mutations which mitigate CQ's antimalarial inhibitory effect on hemozoin biocrystallization by mediating its efflux from the DV (35) . Consequently, it will be clinically relevant to discriminate novel hits whose primary mode of action does not rely upon the parasite's heme detoxification pathway (HDP). As ␤-hematin is chemically and structurally equivalent to hemozoin, an optimized de novo ␤-hematin assay was adopted (36) and distinguished MMV676380, MMV085071, and MMV687812 as non-CQ-like hits from the array of 10 hits. These three hits inhibited ␤-hematin formation to a significantly lower extent than CQ (Fig. 3) , and the in vitro resistance indices obtained via growth inhibition IC 50 assays (Table 1 ) supported this observation. While a significantly greater dosage of MMV687812 was required to inhibit strain K1 than strain 3D7 (Fig. 4) , MMV687812 remained a promising hit according to its resistance index relative to the resistance index exhibited by CQ. Furthermore, in vitro assays and sequencing analyses have identified a minimum threshold of a 10-fold difference in IC 50 s between sensitive and multidrug-resistant P. falciparum strains to be a robust cutoff against a false-positive resistance indication (37) . With a resistance index of 2.58, MMV687812, together with MMV676380 and MMV085071, thus continued to be categorized as non-CQ-like compounds. Overall, IC 50 s in the low-micromolar and nanomolar range for the 3D7, K1, IPC 5202, and Cam3.I_rev strains affirmed the antimalarial abilities of the compounds, even though the efficacies were lower than those of the established antimalarials CQ and ART (Fig. 7) , indicating the lack of in vitro cross-resistance.
Rapidly acting drugs are likely to eliminate circulating parasites faster and avoid recrudescence and resistance development from suboptimal exposure to the drugs. In a Four of the compounds were from the tuberculosis disease cluster, as they were first assayed against Mycobacterium tuberculosis during the curation of the MMV Pathogen Box, while 6 of them were assayed for activity against P. falciparum.
vitro killing rates revealed, unsurprisingly, that there was no association between antimalarial potency, as indicated by the IC 50, and the killing rate, given that the compound-specific lag phase is independent of the potency of the dose (38) . Metabolism-based assays often have limitations, in that some drugs, such as ciprofloxacin, clindamycin, and azithromycin, have been reported to display a delayed death effect (39) , and metabolic proxies as markers of parasite viability, such as parasite lactate dehydrogenase (pLDH) or histidine-rich protein 2 (HRP-2) levels, therefore do not always truly reflect the killing rates. For instance, bioconversion studies on a choline analog, T3/SAR97276, developed by Sanofi-Aventis showed rapid metabolism of the prodrug within 2 h (40), but data from metabolism-based assays of pLDH and HRP-2 failed to correlate with the analog's efficacy at subnanomolar IC 50 s and the rapid onset of parasite clearance observed in vivo (41) . Parasite viability following intraerythrocytic reinvasion, coupled with time point-specific drug removal, is thus a more suitable readout. By the 72nd hour of investigation, MMV085071 was able to produce low levels of parasitemia similar to those produced by CQ and ART, thereby suggesting that even though the lag phase (the time taken for a compound to exert its outcome of maximal parasite killing) was longer, MMV085071 could achieve an overall efficacious abrogation of P. falciparum growth (Fig. 6) . Conversely, MMV676380, MMV687812, PYR, and ATV were slower acting, with a marked reduction in the level of parasitemia being achieved only after the first parasite cycle. In light of this, parasite recovery from the lack of complete clearance could be expected should the duration of investigation be extended over 2 developmental cycles when the drug concentration falls below desired levels. Nonetheless, moderately or slower-acting drugs, such as azithromycin, showed in vitro and in vivo synergistic efficacy with ART or quinine (42), while CQ treatment supplemented with doxycycline demonstrated a significant improvement in parasite clearance in patients (43) . Since artemisinin resistance status is attributed to delayed clearance, therapeutically potent yet slow-acting drugs could be administered in combination to prevent recrudescence once the rapid parasiticidal action of artemisinin has worn off. Assays with tightly synchronized ART-resistant parasites at the ring stage (44) could be performed with artemisinin-based compounds to better assess the potentiating effects of MMV676380 and MMV687812 against artemisinin resistance and reinvasion capacity, as implied by an enhanced susceptibility when pulsed in dosespecific combinations with ART or dihydroartemisinin.
According to compound report cards deposited in chEMBL (the Neglected Tropical Disease Archive), non-cross-resistant hits MMV085071, MMV676380, and MMV687812 do not contain structural alerts or any violations of Lipinski's rule of 5, both of which are important considerations to assess the drug likeness of uncharacterized compounds. The 50% cytotoxic concentration (CC 50 ) of MMV687812 for HepG2 cells, however, was reported to be 3.9 M, while the IC 50 s against P. falciparum 3D7 and K1 were in the high-nanomolar to low-micromolar range (Table 1 ; see also Fig. S1 in the supplemental material). With an overall therapeutic index of 6.2, this may indicate inherent cytotoxicity and weak selectivity. MMV676380 offers an improved selectivity with a therapeutic index of over 50. Notably, MMV085071 proved to be a top lead compound from the series of studies undertaken, as the work described here revealed its rapidly acting parasiticidal kinetics, a potency of PCD-like induction comparable to that of CQ, and its low-nanomolar efficacy against 3D7 (IC 50 , 76 nM) and K1 (IC 50 , 127 nM). With a therapeutic index of over 125, it is reasonable to speculate that MMV085071 has a satisfactory safety profile. Surprisingly, a higher inhibitory dosage was observed for field isolates (Fig. 7) than for laboratory strains (Fig. 4) .
MMV085071, which is categorized in the malaria disease cluster set to have potent activity against 3D7 and W2 parasites (CQ resistant), was also previously reported by Novartis (PubChem GNF-Pf-3843). Structurally, MMV085071, also known as 2-(5-methoxy-3-pyridinyl)-6-[4-(4-pyridinyl)-1-piperazinyl]pyrazine, contains pyridine, piperazine, and pyrazine drug-like chemical moieties, which are also basic heterocyclic amines. Pyrazine rings have long been involved in a range of antimycobacterial (in the form of pyrazinamide), anticancer, and insecticidal effects (45) . Novel analogues with pyrazine substitutes were proposed to inhibit protein kinases while modulating cancer cells' sensitivity toward apoptosis and anticancer chemotherapy (46) . Piperazine rings are popular constituents of pharmaceutical agents, and specifically, pyridinylpiperazine and pyrimidinylpiperazine pharmacophores, similar to the pharmacophore of MMV085071, are commonly recommended as medications for neurological disorders, such as depression (mirtazapine) and Parkinson's disease (piribedil). These chemical scaffolds also demonstrated anticancer and antiretroviral characteristics against Bcr-Abl tyrosine kinase and HIV, respectively (47, 48) .
Tracking along the database details in PubChem and chEMBL, MMV085071/GNF-Pf-3843 was identified from a high-throughput screen (1.7 million compounds) of the Novartis compound library in 2008. Substitution of the pyridine ring with an alkyl amine group in MMV085071/GNF-Pf-3843 gave rise to another compound, GNF-Pf-1610, which showed a significant reduction of potency against 3D7 and CQ-resistant strain W2 compared with that of MMV085071. A more than 7-fold increase in the dosage of GNF-Pf-1610 compared with that of MMV085071 was required for activity against both 3D7 and W2 parasites (49) . Accordingly, this revealed preliminary insights into the structure-activity relationship (SAR) of MMV085071/GNF-Pf-3843, suggesting that the pyridine moiety is essential for its parasiticidal activity. The identification and characterization of MMV085071 thus indicate that it is a potential novel candidate for downstream hit-to-lead optimization.
In summary, the MMV Pathogen Box was subjected to a robust, high-content phenotypic screen for compounds that permeabilize DV, followed by flow cytometric analysis of the compounds for MOMP and DNA degradation. From that screen, 10 hits were subjected to further characterization studies. To narrow the panel of hits inducing a PCD-like phenotype, dose-response experiments on parasites with PCD phenotypes and CQ and ART resistance were performed, and MMV676380, MMV085071, and MMV687812 were found to be active against the CQ-resistant K1 strain and the ART-resistant IPC 5202 strain. MMV085071, however, exhibited the lowest IC 50 and had efficacy comparable to that of CQ in the induction of PCD-like phenotypes in P. falciparum. While its precise mode of action is not yet elucidated, low-micromolar concentrations of MMV085071 were able to trigger DV disruption and induce downstream PCD-like features and parasite cell death within a short incubation time of 4 h, suggesting that its mode of action is via a PCD-like mechanism. Additional studies on killing kinetics uncovered that it is a fast-acting compound, further reinforcing he possibility that it is a novel drug candidate with activity against the human malaria parasite. Quantitative SAR analysis and hit-to-lead optimization of MMV085071 through analogues can be conducted, thus providing a strong basis for in-depth mechanistic studies and drug development. were cultured and maintained in 25-cm 2 or 75-cm 2 nonvented cell culture flasks at 1.25% hematocrit with complete malaria culture medium (MCM), comprising a filter-sterilized homogeneous mixture of RPMI 1640 (Life Technologies, USA), 2.2 g/liter sodium bicarbonate, 0.5% (wt/vol) AlbuMAX II (Gibco, Thermo Fisher Scientific, MA, USA), 0.005% (wt/vol) hypoxanthine (Sigma-Aldrich, MO, USA), 0.03% (wt/vol) L-glutamine (Sigma-Aldrich, MO, USA), and 25 g/liter gentamicin (Gibco, Thermo Fisher Scientific, MA, USA). The pH was adjusted to 7.4 using 1 N NaOH. Type O-positive human erythrocytes in citrate-phosphate-dextrose with adenine (CPDA-1) anticoagulant were obtained from the Interstate Blood Bank (Memphis, TN, USA) and tested negative for infectious agents according to FDA guidelines. The flasks were incubated at 37°C without light and gassed with 5% CO 2 , 3% O 2 , and 92% N 2 . Routine PCR-based mycoplasma testing was conducted on a monthly basis to ensure the lack of contamination in cultures. Parasites were synchronized with 5% (wt/vol) sorbitol (Merck, Darmstadt, Germany) at 37°C for 10 min for the selection of ring-stage parasites, following which the cells were washed twice and resuspended to 1.25% hematocrit in MCM.
MATERIALS AND METHODS

In vitro
Drug preparation and MMV Pathogen Box library storage. CQ, pyrimethamine (PYR), atovaquone (ATV), artesunate (ART), and mefloquine (MQ) were all purchased from Sigma-Aldrich. CQ was dissolved Screen for Plasmodium DV-Disrupting Molecules Antimicrobial Agents and Chemotherapy in sterile 1ϫ phosphate-buffered saline (PBS), while the remaining drugs were dissolved in sterile dimethyl sulfoxide (DMSO) to stock aliquots of 10 mM, frozen at Ϫ20°C, and protected from light. Fresh working drug concentrations were prepared after dilution with sterile PBS or cold MCM to ensure that the final assay mixture contained less than 0.5% DMSO. The MMV Pathogen Box was received from both the Singapore University of Technology and Design, Singapore, and the Medicines for Malaria Venture (MMV; Switzerland) in Costar 96-well round-bottom microtiter plates. Upon receipt, each plate was sealed with 96-well X-Pierce adhesive film (Sigma-Aldrich, MO, USA), and all wells, each of which contained 10 l of 10 mM drug, were reconstituted with DMSO so that the final stock concentration was 1 mM in 100 l, according to MMV's instructions. Similarly, the plates were stored in Ϫ20°C and kept protected from light. Parasite drug treatment and staining. 3D7 parasites were synchronized for 2 cycles prior to the start of the assay to achieve a high level of parasitemia of over 10% with mid-trophozoite-stage parasites (28 to 30 h postinvasion), which were resuspended to 2.5% hematocrit in a 96-well flat-bottom plate. After drug treatment and incubation at 37°C with a mixture of gases in a humidified hypoxic chamber for 4 h (for the DV disruption experiments), cells were transferred to a 96-well V-bottom plate to concentrate the pellet and stained with 1 M Fluo-4 AM (Thermo Fisher Scientific, MA, USA) and 1 g/ml Hoechst 33342 (Sigma-Aldrich, MO, USA). Following incubation in the dark for 30 min, the cells were washed thrice with prewarmed MCM, resuspended in 100 l of HyClone PBS (GE Healthcare, Chicago, IL, USA), and sealed with X-Pierce adhesive film to prevent evaporation from the wells during data acquisition. For assays validating a PCD-like response with the parasites' mitochondria and assays of DNA integrity, the trophozoites were incubated for 10 h under the same atmospheric conditions described above, stained with 6 M JC-1 (Thermo Fisher Scientific, MA, USA) and 0.8 g/ml Hoechst 33342, and subjected to the same washing steps described above.
DV permeabilization screen with a flow cytometer. The ImageStream X MkII flow cytometer (Amnis, Darmstadt, Germany) is designed to have imaging properties for high-content single-cell analysis. In addition to the analysis of cell populations based on fluorescence, bright-field and twodimensional fluorescent images of each event could be captured and visualized. Leveraging on its cell imaging capabilities, a high-content primary screen was developed and optimized (50) to detect and quantitatively assay for the increase in the area of Fluo-4 fluorescence as a consequence of drugmediated DV disruption and Ca 2ϩ redistribution from the DV to the parasite cytosol. Using a 60ϫ objective and extended depth of field (EDF) element, each 96-well plate was assayed with the autosampler plate reader for high-throughput data acquisition. Hoechst 33342 is a lipophilic DNA-binding fluorescent stain that is excited by a 375-nm UV laser at 10 mW, while Fluo-4 AM is a cell-permeant calcium-sensing dye which is excited by an argon ion 488-nm laser at 200 mW. Stringent gating was applied during data acquisition to select for focused, round Hoechst 33342-positive singlet parasites on the basis of the area and aspect ratio of the cells in the bright-field channel and the fluorescence intensity of Hoechst 33342. Having acquired 2,000 parasite events, data analysis was performed with IDEAS software (version 6.1). The gating strategy is elucidated in Fig. 1 . All of the acquired events were gated for focused cells on a gradient root mean square (RMS) for image sharpness histogram, followed by development of a scatter plot of the aspect ratio against the area for the bright-field images (Fig. 1a) . This ensures that the parasite images and events analyzed are sharp and focused singlets. Gating for trophozoites was based on fluorescence intensity and visual inspection of the captured images. Single trophozoites which matured to the schizont stage during the 4-h duration of data acquisition displayed multiple punctate forms of Hoechst-stained DNA-containing merozoites, on the basis of the Hoechst staining intensity and as verified with visual images. Since schizonts mature with a larger DV during the parasite life cycle, they were not included in the analysis. Once applied, the gating for trophozoites was maintained in all subsequent analyses. Untreated drug-free PBS-treated controls were included in all experimental runs, and healthy PBS-treated parasites displayed an intact DV with little Fluo-4 redistribution, as Ca 2ϩ remained sequestered in the DV (Fig. 1b) . To quantify single-cell DV disruption, an area feature mask incorporated in IDEAS software was applied to measure the increase in the Fluo-4 fluorescence area upon binding to the effluxed intravacuolar Ca 2ϩ (Fig. 1c) . Raw feature values were normalized, and the degree of DV disruption achieved with the test compounds was compared to that achieved with CQ. Single-stain (Hoechst 33342 and Fluo-4 AM) controls were prepared fresh for every run of the experiment, and a compensation matrix was generated using the compensation algorithm of the software.
Assays for validation of PCD-like phenotype by MOMP and loss of DNA content. The ratiometric JC-1 dye is dependent on the mitochondrial membrane potential and was used for the assessment of mitochondrial depolarization by flow cytometry. The shift of the fluorescence emission from JC-1-stained green monomers (529 nm) to JC-1-stained red aggregates (590 nm) is indicative of a high membrane potential in healthy functional mitochondria, while mitochondrial degradation is denoted by a reduction in the percentage of JC-1-stained red aggregates to JC-1-stained green monomers. Using an Attune NxT flow cytometer (Invitrogen, CA, USA), a 405-nm violet excitation laser fitted with a 417LP 440/50BP filter was used to excite and detect Hoechst 33342, while a blue light excitation laser (Alexa Fluor 488 nm) fitted with a 503LP 530/30BP filter and a yellow light excitation laser (561 nm) fitted with a 577LP 585/16BP filter were used to excite and detect JC-1. At least 100,000 events were acquired from each sample. Gating for sub-G 1 DNA peaks, as an indication of DNA degradation, relative to that for the untreated Hoechst-positive controls was determined.
Spectrophotometric determination for inhibition of ␤-hematin formation. To mature and proliferate, P. falciparum biocrystallizes toxic heme by-products into hemozoin crystals through the parasite's heme detoxification pathway (HDP) during hemoglobin degradation. CQ had been widely proposed to inhibit parasite growth by upsetting the biocrystallization process. ␤-Hematin was previously established to be the chemical equivalent of hemozoin (51) . As this study was interested in the discovery of novel potent antimalarials, the hits were subjected to a preliminary assessment of possible CQ cross-resistance on the basis of ␤-hematin inhibition. To characterize the 10 hits, CQ was included as a control for a CQ-like mechanism of inhibition of the HDP. PYR served as a non-CQ-like mechanistic control because its mechanism of action primarily disrupts folate and DNA synthesis (52) . In accordance with the rationale, a spectrophotometric assay was performed to select for hits which did not inhibit ␤-hematin formation. Nonidet P-40 (Roche, Basel, Switzerland) was used as a biological mimic of parasite lipid factors to catalyze the formation of ␤-hematin from hemin (53) . Drug-free controls were treated with PBS, while sample tubes were treated with the compounds of interest (CQ, PYR, and the 10 hits) at a final concentration of 20 M. The final reaction mixtures were maintained at 400 l with bovine hemin (Sigma-Aldrich, MO, USA) at 1 mM, 30.5 M Nonidet P-40 in acetate buffer at pH 5.0, akin to the acidic pH of the parasite DV (54) . The reagents used for the sodium acetate buffer (100 mM, pH 5.0), Tris-HCl buffer (100 mM, pH 8.0) with 2.5% (wt/vol) SDS, and sodium bicarbonate buffer (100 mM, pH 9.2) preparations were purchased from Sigma-Aldrich. After a 14-h incubation at 37°C and 195 rpm, the tubes were centrifuged at 32,000 ϫ g for 10 min at 4°C and resuspended in prewarmed Tris-HCl buffer containing 2.5% (wt/vol) SDS for 30 min at 37°C to remove unbound proteins, followed by prewarmed alkaline sodium bicarbonate buffer to solubilize heme aggregates and precipitate the ␤-hematin (36). The final ␤-hematin pellet was washed with distilled water and resuspended in 100 l 1 N NaOH and 900 l 2.5% (wt/vol) SDS. The samples were then read with a Tecan Infinite 200 Pro microplate reader at 405 nm for detection of ␤-hematin. Relative absorbance readings were normalized to the background reading (that for the PBS-treated drug-free controls). CQ and hits which inhibited ␤-hematin formation would have lower absorbance readings by this spectrophotometric assay, while PYR and hits which did not inhibit ␤-hematin formation would exhibit higher absorbance values.
A 48-h reinvasion assay for IC 50 determination. Ring-stage parasites synchronized for 1 cycle prior to the start of the 48-h reinvasion assay for half-maximal (50%) inhibitory concentration (IC 50 ) determination were incubated for 48 h at 1.25% hematocrit and 0.7% parasitemia (for strain 3D7) or 1% parasitemia (for strains K1, Cam3.I_rev, and IPC 5202) with 11-point serial dilutions of the reference antimalarial drugs and the compounds of interest. Parasite labeling was carried out with 1 g/ml Hoechst 33342 for 30 min at 37°C, and at least 100,000 events were collected by the Attune NxT flow cytometer, as elaborated above. IC 50 s were then determined by GraphPad Prism (version 5) software using a variable-slope logistic curve. Values were obtained from at least 3 separate triplicates.
Kinetics of P. falciparum parasite killing by compound hits. To determine if the compounds of interest were rapid or slower acting, parasites were treated with the drugs of interest at concentrations that were 10 times the IC 50 s predetermined prior to this assay (see Table S1 in the supplemental material). This concentration ensured that any observed delayed killing effect was not due to suboptimal exposure of the parasites to the drug treatment but was attributed to the slower killing kinetics of the drug against P. falciparum. From the point of drug treatment (time zero), parasites were harvested at 24 h, 48 h, and 72 h. During parasite harvesting, the drugs were washed off with MCM at least 3 times. In this assay, parasites were treated with reference antimalarial drugs (CQ and ART for rapid-acting drugs, PYR and ATV for slower-acting drugs) and the Pathogen Box hits (MMV676380, MMV085071, and MMV687812) at 5% parasitemia and 0.5% hematocrit under conditions similar to those used for the IC 50 assay. After harvesting and drug removal, 10 M Vybrant CFDA-SE (Thermo Fisher Scientific, MA, USA)-prelabeled erythrocytes at 2.5% hematocrit were added to the parasites and further incubated under the same conditions described above for an additional parasite cycle (48 h) to allow invasion into the labeled erythrocytes. The level of parasitemia in each well was determined with Hoechst 33342 labeling and acquired using the Attune NxT flow cytometer. Parasite viability and the reinvasion capacity at all time points were indicated by a double-positive population (positive for both CFDA-SE and Hoechst 33342 staining) and were normalized to those for the drug-free PBS-treated controls at time zero. At least 3 separate experiments were performed at all time points (0 h, 24 h, 48 h, and 72 h).
Statistical tests and analyses. Graphs were prepared and statistical tests were performed with GraphPad Prism (version 5.0) software, which was also used to obtain P values by two-sample Student's t tests. Error bars represent the standard errors of the means (SEMs) from at least 3 separate independent experiments.
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